Page last updated: 2024-11-13
jwh 250
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 44397540 |
| CHEMBL ID | 188031 |
| SCHEMBL ID | 11983322 |
| MeSH ID | M0569801 |
Synonyms (32)
| Synonym |
|---|
| c22h25no2 |
| CHEMBL188031 , |
| jwh-250 |
| jwh 250 |
| 2-(2-methoxy-phenyl)-1-(1-pentyl-1h-indol-3-yl)-ethanone |
| bdbm50170335 |
| 2-(2-methoxyphenyl)-1-(1-pentyl-1h-indol-3-yl)ethanone |
| 864445-43-2 |
| ip9911r8a0 , |
| 1-pentyl-3-(2-methoxyphenylacetyl)indole |
| unii-ip9911r8a0 |
| dea no. 6250 |
| AKOS015999864 |
| FT-0670594 |
| CCG-208724 |
| ethanone, 2-(2-methoxyphenyl)-1-(1-pentyl-1h-indol-3-yl)- |
| 2-(2-methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone |
| j2.884.535i , |
| DTXSID40235556 |
| Q-200139 |
| jwh-250 (1-pentyl-3-(2-methoxyphenylacetyl)indole) |
| SCHEMBL11983322 |
| DS-3158 |
| 2-(2-methoxyphenyl)-1-(1-pentyl-1h-indol-3-yl)ethan-1-one |
| jwh-250 (2-(2-methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone) 1.0 mg/ml in acetonitrile |
| jwh-250 (2-(2-methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone) |
| jwh-250 (2-(2-methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone) 0.1 mg/ml in acetonitrile |
| ethanone, 2-(2-methoxyphenyl)-1-(1-pentyl-1h-indol-3-yl)-, jwh-250 |
| NCGC00386575-01 |
| Q4041747 |
| jwh-250, 1mg/ml in methanol |
| jwh-250, 0.1mg/ml in methanol |
Research Excerpts
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (8)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 1.1988 | 0.0123 | 7.9835 | 43.2770 | AID1645841 |
| G | Vesicular stomatitis virus | Potency | 1.8999 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| Interferon beta | Homo sapiens (human) | Potency | 1.8999 | 0.0033 | 9.1582 | 39.8107 | AID1645842 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 1.8999 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 1.8999 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 1.8999 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Cannabinoid receptor 1 | Rattus norvegicus (Norway rat) | Ki | 0.0110 | 0.0002 | 0.5665 | 10.0000 | AID238758 |
| Cannabinoid receptor 2 | Homo sapiens (human) | Ki | 0.0330 | 0.0000 | 0.4156 | 10.0000 | AID238759; AID419195 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (56)
Molecular Functions (19)
Ceullar Components (25)
Bioassays (12)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID238759 | Binding affinity to displace [3H]CP-55940 from cloned human CB2 receptor | 2005 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 15, Issue:18 | 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. |
| AID419194 | Displacement of [3H]CP-55940 from CB1 receptor in rat brain by filtration assay | 2009 | European journal of medicinal chemistry, Jun, Volume: 44, Issue:6 | Development of CoMFA and CoMSIA models of affinity and selectivity for indole ligands of cannabinoid CB1 and CB2 receptors. |
| AID243030 | Ratio of the binding affinity towards CB1 receptor to that of CB2 receptor | 2005 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 15, Issue:18 | 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. |
| AID419196 | Selectivity ratio of pKi for CB1 receptor in rat brain to pKi for human cloned CB2 receptor | 2009 | European journal of medicinal chemistry, Jun, Volume: 44, Issue:6 | Development of CoMFA and CoMSIA models of affinity and selectivity for indole ligands of cannabinoid CB1 and CB2 receptors. |
| AID419197 | Selectivity ratio of pKi for human cloned CB2 receptor to pKi for CB1 receptor in rat brain | 2009 | European journal of medicinal chemistry, Jun, Volume: 44, Issue:6 | Development of CoMFA and CoMSIA models of affinity and selectivity for indole ligands of cannabinoid CB1 and CB2 receptors. |
| AID238758 | Binding affinity to displace [3H]CP-55940 from CB1 receptor of rat brain | 2005 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 15, Issue:18 | 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. |
| AID419195 | Displacement of [3H]CP-55940 from human cloned CB2 receptor by filtration assay | 2009 | European journal of medicinal chemistry, Jun, Volume: 44, Issue:6 | Development of CoMFA and CoMSIA models of affinity and selectivity for indole ligands of cannabinoid CB1 and CB2 receptors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 36.61
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (36.61) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||